source
- Abivax remains independent despite intense acquisition speculationBiotech merger activity is at record levels, yet the French company Abivax, which is developing the ulcerative colitis drug obefazimod, has not been bought. Rumors have floated about a potential $…
- CBER official overturns Replimune melanoma drug rejection; AbbVie reports phase 3 success in multiple myelomaA CBER regulator has reversed a prior decision to reject Replimune's experimental melanoma therapy, allowing the program to move forward. AbbVie announced that its multiple myeloma candidate achie…